Condition

Anaplastic Thyroid Cancer

ClinicalTrials.gov condition label

Clinical trials4

Recruiting0

Common interventions6

Lead sponsors shown3

Clinical trials

4 shown

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsNCT04579757 · 2021-03-05

Phase I/II Study of PDR001 in Patients With Advanced MalignanciesNCT02404441 · 2015-04-27

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497 · 2003-08-01

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNCT00004074 · 1999-08-01

Common interventions

ABI-007/carboplatin/trastuzumabBIOLOGICAL1 gefitinibDRUG1 PDR001BIOLOGICAL1 recombinant interleukin-12BIOLOGICAL1 Surufatinib and Tislelizumab _ Part 1DRUG1 Surufatinib and Tislelizumab _ Part 2DRUG1

Leading sponsors

National Cancer Institute (NCI)2 Hutchmed1 Novartis Pharmaceuticals1

Trial status mix

COMPLETED3

TERMINATED1

Phase mix

PHASE13

PHASE22

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.